cocaine has been researched along with risperidone in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.71) | 18.2507 |
| 2000's | 18 (64.29) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Sen, S; Sinha, N | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Keserü, GM | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Roy, A; Roy, M; Smelson, DA | 2 |
| Dashevsky, BA; Frank, RA; Grocki, S; Kehne, JH; Schmidt, CJ; Sorensen, SM; Tsibulsky, VL | 1 |
| Bailey, R; Creson, D; Grabowski, J; Rhoades, H; Schmitz, JM; Silverman, P; Stotts, A | 1 |
| Baldessarini, RJ; Tarazi, FI; Zhang, K | 1 |
| Gessa, GL; Marchese, G; Pani, L; Ruiu, S; Saba, PL | 1 |
| Kalechstein, AD; Ling, W; Newton, TF; Tervo, K; Uslaner, J | 1 |
| Broderick, PA; Rahni, DN; Zhou, Y | 1 |
| Cowan, K; Dougherty, A; Grabowski, J; Hassan, S; Kopecky, C; Moeller, FG; Rhoades, H; Schmitz, J; Stotts, A | 1 |
| Clifton, PG; Hartfield, AW; Moore, NA | 1 |
| Connor, DF; Melloni, RH; Morrison, RL; Ricci, LA; Schwartzer, JJ | 1 |
| Alvarez, Y; Farré, M; Pérez-Mañá, C; Torrens, M | 1 |
| Correll, CU; Iwata, N; Kishi, T; Matsuda, Y | 1 |
| Banks, ML; Hutsell, BA; Negus, SS | 1 |
| Makiguchi, A; Okada, T; Shioda, K; Suda, S | 1 |
2 review(s) available for cocaine and risperidone
| Article | Year |
|---|---|
Antipsychotic drugs in cocaine dependence: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Cocaine; Cocaine-Related Disorders; Humans; Outcome Assessment, Health Care; Patient Dropouts; Randomized Controlled Trials as Topic; Risperidone; Severity of Illness Index | 2013 |
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Dopamine; Dopamine Uptake Inhibitors; Humans; Methamphetamine; Olanzapine; Outcome Assessment, Health Care; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Substance Withdrawal Syndrome; Synaptic Transmission; Treatment Outcome | 2013 |
3 trial(s) available for cocaine and risperidone
| Article | Year |
|---|---|
Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients.
Topics: Antipsychotic Agents; Behavior, Addictive; Cocaine; Cocaine-Related Disorders; Cues; Drive; Humans; Male; Prospective Studies; Risperidone; Substance Withdrawal Syndrome; Treatment Outcome | 1997 |
Risperidone for the treatment of cocaine dependence: randomized, double-blind trial.
Topics: Adult; Cocaine; Cocaine-Related Disorders; Dopamine Antagonists; Double-Blind Method; Female; Humans; Male; Patient Dropouts; Psychotherapy; Recurrence; Risperidone; Time Factors | 2000 |
Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials.
Topics: Adolescent; Adult; Blood Pressure; Cocaine; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Dextroamphetamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Heroin Dependence; HIV Infections; Humans; Male; Methadone; Middle Aged; Narcotics; Patient Dropouts; Psychiatric Status Rating Scales; Risperidone; Substance Abuse Detection | 2004 |
23 other study(ies) available for cocaine and risperidone
| Article | Year |
|---|---|
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Risperidone and neuropsychological test performance in cocaine-withdrawn patients.
Topics: Adult; Antipsychotic Agents; Cocaine; Humans; Male; Neuropsychological Tests; Risperidone; Substance Withdrawal Syndrome; Substance-Related Disorders | 1997 |
Mixed D2/5-HT2A antagonism of cocaine-induced facilitation of brain stimulation reward.
Topics: Animals; Brain; Cocaine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Male; Piperidines; Rats; Rats, Sprague-Dawley; Reward; Risperidone; Self Stimulation; Serotonin Antagonists | 1998 |
Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Carrier Proteins; Caudate Nucleus; Cocaine; Dibenzothiazepines; Dopamine Plasma Membrane Transport Proteins; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Nucleus Accumbens; Olanzapine; Paroxetine; Pirenzepine; Prosencephalon; Putamen; Quetiapine Fumarate; Radioligand Assay; Rats; Rats, Sprague-Dawley; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Tritium | 2000 |
The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex.
Topics: Animals; Clozapine; Cocaine; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Frontal Lobe; Haloperidol; Ketanserin; Male; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Risperidone; Ritanserin; Serotonin Antagonists; Synaptosomes; Tritium | 2000 |
Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine.
Topics: Adult; Analysis of Variance; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Dopamine Antagonists; Dose-Response Relationship, Drug; Euphoria; Female; Humans; Male; Middle Aged; Risperidone; Serotonin Antagonists | 2001 |
Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior.
Topics: Animals; Cocaine; Dopamine; Electrochemistry; Exploratory Behavior; Locomotion; Male; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin | 2003 |
Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats.
Topics: Animals; Antipsychotic Agents; Cocaine; Dibenzothiazepines; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Eating; Fat Emulsions, Intravenous; Female; Hyperkinesis; Male; Motor Activity; Piperazines; Quetiapine Fumarate; Rats; Risperidone; Thiazoles | 2006 |
Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression.
Topics: Age Factors; Aggression; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Body Weight; Cocaine; Cricetinae; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Mesocricetus; Phenotype; Reaction Time; Risperidone | 2008 |
Effects of 21-day d-amphetamine and risperidone treatment on cocaine vs food choice and extended-access cocaine intake in male rhesus monkeys.
Topics: Animals; Central Nervous System Stimulants; Choice Behavior; Cocaine; Dextroamphetamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Food; Macaca mulatta; Male; Risperidone; Self Administration | 2016 |
Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats.
Topics: Animals; Benzazepines; Cocaine; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Hyperthermia; Ketanserin; Male; Rats; Rats, Wistar; Risperidone; Ritanserin; Serotonin 5-HT2 Receptor Antagonists | 2020 |